Enrollment Done Right: How Collaborative Site Networks Exceed What Individual Effort Cannot
Behind every breakthrough therapy is a race against time. We made sure this one won - for a UK MedTech company's clinical trial, turning ambitious targets into a success story.
Patient enrollment is where most clinical trials fall short. Timelines slip, targets are trimmed, and sponsors accept less than they planned for. When a UK MedTech company developing a next-generation orthobiologics therapy needed a full-service partner to make their clinical trial enrollment work, aCROss Medical's sites did not just meet the target. They exceeded it, completing full enrollment at an extremely fast pace, well ahead of the original plan and far beyond what the sponsor had anticipated.
The Enrollment Problem in Clinical Trials
Patient recruitment is consistently identified as the single greatest operational challenge in clinical research. Studies routinely enroll at a fraction of their planned rate. Timelines extend by months or years. Budgets overrun. Sponsors make difficult decisions about whether to reduce endpoints, expand eligibility criteria, or accept underpowered datasets.
The numbers tell a stark story: more than 80% of clinical trials fail to meet their original enrollment timelines. Nearly a third are delayed by six months or more due to recruitment shortfalls. For sponsors developing innovative therapies with finite runways, these delays are not just inconvenient. They can be existential.
The root causes are well understood but hard to solve in practice: insufficient site identification rigor, poor patient screening processes, weak site engagement, and a lack of coordinated effort across the network. Sites that work in isolation rarely outperform their individual baseline. Sites that work together, under focused coordination, can achieve something different entirely.
Enrollment is not a passive process. It is an active, coordinated campaign. And when sites work as a unified network toward a shared target, the results speak for themselves.
The Study
The sponsor was an innovative UK MedTech company at the forefront of orthobiologics: developing next-generation biological therapies for musculoskeletal conditions where current treatments fall short. Their investigational device holds an FDA Breakthrough Device designation, a recognition reserved for technologies that demonstrate the potential to provide more effective treatment of serious conditions than currently available alternatives. That designation underscores both the scientific significance of the program and the urgency of moving it forward without delay.
Their clinical trial required recruiting patients with specific orthopedic profiles across multiple sites, with a demanding enrollment timeline set to support an aggressive regulatory and commercial roadmap.
They engaged aCROss Medical to deliver end-to-end clinical trial services, from the earliest stages of site identification and feasibility assessment all the way through patient recruitment, data management, and ongoing monitoring. It was a full partnership engagement, not a single-service contract, and we approached it accordingly.
Why This Was Challenging
Specialist Patient Population
Orthobiologics trials require patients with specific musculoskeletal diagnoses, surgical indications, and clinical histories. The screening burden is high, the eligible pool is narrower than it appears on paper, and sites must invest significant effort per enrolled patient.
Ambitious Targets, Tight Timeline
The sponsor had set ambitious recruitment goals aligned with a precise regulatory timeline. Missing the target was not simply a delay. It would have downstream consequences for the entire development program.
Full-Scope Coordination Required
With aCROss Medical responsible for site identification, feasibility, recruitment, data management, and monitoring simultaneously, operational alignment across all workstreams had to be seamless. A gap in any one area would have affected the others.
How We Made It Work
Rigorous Site Identification and Feasibility
We did not select sites based on convenience or existing relationships alone. We conducted thorough feasibility assessments to identify sites with genuine access to the right patient population, the clinical infrastructure to run the study properly, and the team commitment to prioritize enrollment. The right sites at the start is the most important enrollment decision a study makes.
Sites Operating as a Unified Network
Rather than letting each site operate independently toward its individual target, we coordinated enrollment across the network actively. Sites shared approaches, escalated screening challenges early, and supported each other's momentum. The mutual effort was the difference. No single site achieved this result alone. The network did.
Practical, Solutions-Oriented Approach
Enrollment campaigns encounter obstacles. Patient screening rates fluctuate. Site-level issues arise. Rather than escalating problems, we resolved them at the operational level, quickly and without drama. The sponsor always knew what was happening, but rarely needed to intervene, because our team was already acting.
Consistent, Open Communication
We maintained close communication with the sponsor throughout. Readily available for routine updates and responsive on time-sensitive matters. Transparent about where we stood against targets. And open to discussion at every stage, whether the conversation was straightforward or complex. The sponsor always had a partner they could reach.
The Outcome
Our sites, working in coordinated mutual effort, completed full enrollment at an extremely fast pace, well ahead of the planned timeline and far beyond what the sponsor had set as their most ambitious target.
The sponsor's Clinical Director described us as "a strong and highly reliable partner for clinical research activities." That assessment came while enrollment was still ongoing, a reflection not just of results, but of the speed, reliability, and quality of the way we work every day.
"We partnered with aCROss Medical on a study that required a broad range of services, from site identification and feasibility through to patient recruitment, data management and ongoing monitoring activities. From the outset, their team demonstrated a strong understanding of our core study objectives and brought a practical, solutions-oriented approach at every stage of the project. Throughout, their team was readily available, easy to contact, and consistently open to discussion, whether for routine updates or more complex, time-sensitive matters. Most notably, they ensured we not only met but exceeded our ambitious targets for patient recruitment, underlying them as a strong and highly reliable partner for clinical research activities."
What This Case Study Demonstrates
Enrollment is the operational heart of every clinical trial. It is where plans meet reality. When it works, a study moves forward on time, with the data the sponsor needs. When it fails, the consequences ripple through timelines, budgets, and regulatory strategies.
At aCROss Medical, patient recruitment is not a passive promise. It is an active, managed campaign, run by sites that understand the population, coordinators who are solutions-oriented by instinct, and a network that works together rather than in isolation. That is what delivered results here, and it is what we bring to every study we run.
Critically, our team has the knowledge and experience to identify specific challenges early and mitigate them before they become problems. When an obstacle is operational, we solve it. When it goes deeper, touching the protocol, eligibility criteria, treatment parameters, or other study design elements, we bring it to the sponsor promptly and constructively, with a clear picture of what we are seeing on the ground and a proposed path forward. That combination of on-the-ground expertise and transparent sponsor communication is what keeps enrollment on track even when circumstances change.
Let's Talk About Your Enrollment Challenge
Whether your trial has demanding targets, a specialist patient population, or a timeline that cannot slip, we have the network and the expertise to deliver.
Contact Our TeamThe sponsor company and study details have been anonymized. The clinical outcomes and operational details are factual.